|
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia
|
journal
|
July 2014 |
|
BCL-2 protein family: attractive targets for cancer therapy
|
journal
|
November 2022 |
|
An integrated drug-likeness study for bicyclic privileged structures: from physicochemical properties to in vitro ADME properties
|
journal
|
May 2011 |
|
Venetoclax: First Global Approval
|
journal
|
June 2016 |
|
Structural biology of the Bcl-2 family of proteins
|
journal
|
March 2004 |
|
Programmed Anuclear Cell Death Delimits Platelet Life Span
|
journal
|
March 2007 |
|
Structural Insights into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of Conjugation
|
journal
|
September 2008 |
|
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
|
journal
|
April 2020 |
|
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
|
journal
|
January 2018 |
|
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
|
journal
|
January 2018 |
|
Chemo-proteomics exploration of HDAC degradability by small molecule degraders
|
journal
|
October 2021 |
|
HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation
|
journal
|
November 2023 |
|
Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells
|
journal
|
December 2006 |
|
S. pombe Uba1-Ubc15 Structure Reveals a Novel Regulatory Mechanism of Ubiquitin E2 Activity
|
journal
|
February 2017 |
|
Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy
|
journal
|
October 2022 |
|
A Statistical Model for Identifying Proteins by Tandem Mass Spectrometry
|
journal
|
September 2003 |
|
Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds
|
journal
|
May 2017 |
|
Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
|
journal
|
December 2017 |
|
Lowering Lipophilicity by Adding Carbon: One-Carbon Bridges of Morpholines and Piperazines
|
journal
|
September 2018 |
|
Structural Insights into PROTAC-Mediated Degradation of Bcl-xL
|
journal
|
July 2020 |
|
proteiNorm – A User-Friendly Tool for Normalization and Analysis of TMT and Label-Free Protein Quantification
|
journal
|
September 2020 |
|
Establishing Drug Discovery and Identification of Hit Series for the Anti-apoptotic Proteins, Bcl-2 and Mcl-1
|
journal
|
May 2019 |
|
Structure-Based Design of Potent Small-Molecule Inhibitors of Anti-Apoptotic Bcl-2 Proteins
|
journal
|
September 2006 |
|
Structure-Based Design of Potent Bcl-2/Bcl-xL Inhibitors with Strong in Vivo Antitumor Activity
|
journal
|
July 2012 |
|
Structure-Based Discovery of BM-957 as a Potent Small-Molecule Inhibitor of Bcl-2 and Bcl-xL Capable of Achieving Complete Tumor Regression
|
journal
|
October 2012 |
|
Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities
|
journal
|
October 2014 |
|
Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins
|
journal
|
November 2008 |
|
BCL-2 family proteins: changing partners in the dance towards death
|
journal
|
November 2017 |
|
Ubiquitin modifications
|
journal
|
March 2016 |
|
Structural basis of PROTAC cooperative recognition for selective protein degradation
|
journal
|
March 2017 |
|
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|
journal
|
January 2013 |
|
Induced protein degradation: an emerging drug discovery paradigm
|
journal
|
November 2016 |
|
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
|
journal
|
February 2017 |
|
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
|
journal
|
May 2020 |
|
Mutations of MSH5 in nonobstructive azoospermia (NOA) and rescued via in vivo gene editing
|
journal
|
January 2022 |
|
BCL-XL overexpression promotes tumor progression-associated properties
|
journal
|
December 2017 |
|
Chromatogram libraries improve peptide detection and quantification by data independent acquisition mass spectrometry
|
journal
|
December 2018 |
|
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
|
journal
|
January 2019 |
|
Crystal structures of an E1–E2–ubiquitin thioester mimetic reveal molecular mechanisms of transthioesterification
|
journal
|
April 2021 |
|
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
|
journal
|
November 2021 |
|
PROTAC targeted protein degraders: the past is prologue
|
journal
|
January 2022 |
|
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
|
journal
|
January 2019 |
|
The proteostasis network and its decline in ageing
|
journal
|
February 2019 |
|
Plasticity in binding confers selectivity in ligand-induced protein degradation
|
journal
|
June 2018 |
|
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
|
journal
|
June 2019 |
|
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
|
journal
|
December 2019 |
|
Prosit: proteome-wide prediction of peptide tandem mass spectra by deep learning
|
journal
|
May 2019 |
|
PROTACs: past, present and future
|
journal
|
January 2022 |
|
PROTACs bearing piperazine-containing linkers: what effect on their protonation state?
|
journal
|
January 2022 |
|
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
|
journal
|
July 2001 |
|
Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation
|
journal
|
October 2003 |
|
limma powers differential expression analyses for RNA-sequencing and microarray studies
|
journal
|
January 2015 |
|
Targeting BCL-2 regulated apoptosis in cancer
|
journal
|
May 2018 |
|
Phaser crystallographic software
|
journal
|
July 2007 |
|
Coot model-building tools for molecular graphics
|
journal
|
November 2004 |
|
electronic Ligand Builder and Optimization Workbench ( eLBOW ): a tool for ligand coordinate and restraint generation
|
journal
|
September 2009 |
|
XDS
|
journal
|
January 2010 |
|
PHENIX: a comprehensive Python-based system for macromolecular structure solution
|
journal
|
January 2010 |
|
A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models
|
journal
|
September 2021 |
|
Structural and Functional Insights to Ubiquitin-Like Protein Conjugation
|
journal
|
May 2014 |
|
ARC Synergizes with ABT-737 to Induce Apoptosis in Human Cancer Cells
|
journal
|
June 2010 |
|
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
|
journal
|
December 2013 |
|
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
|
journal
|
May 2015 |
|
AMG 176, a Selective MCL1 Inhibitor, is Effective in Hematological Cancer Models Alone and in Combination with Established Therapies
|
journal
|
September 2018 |
|
Bcl-xL–inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets
|
journal
|
August 2011 |
|
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors
|
journal
|
May 2022 |
|
Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
|
journal
|
January 2016 |
|
Cancer Statistics, 2010
|
journal
|
July 2010 |
|
PROTACs: The Future of Leukemia Therapeutics
|
journal
|
September 2022 |
|
From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation
|
journal
|
April 2021 |
|
Resolving the Complexity of Ubiquitin Networks
|
journal
|
February 2020 |
|
Discovery of E3 Ligase Ligands for Target Protein Degradation
|
journal
|
October 2022 |
|
Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression
|
journal
|
November 2010 |